Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
71% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PBYI Guru Trades in Q1 2016

Eaton Vance Worldwide Health Sciences Fund 142,000 sh (New)
John Paulson 70,300 sh (+52.83%)
Steven Cohen 1,157,700 sh (+22.45%)
Jeremy Grantham 2,010,801 sh (-30.66%)
» More
Q2 2016

PBYI Guru Trades in Q2 2016

John Paulson 145,800 sh (+107.40%)
Steven Cohen 1,415,800 sh (+22.29%)
Eaton Vance Worldwide Health Sciences Fund 142,000 sh (unchged)
Jeremy Grantham Sold Out
» More
Q3 2016

PBYI Guru Trades in Q3 2016

Jana Partners 76,074 sh (New)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Steven Cohen 1,028,706 sh (-27.34%)
John Paulson 84,500 sh (-42.04%)
» More
Q4 2016

PBYI Guru Trades in Q4 2016

Jana Partners 142,727 sh (+87.62%)
Steven Cohen Sold Out
John Paulson 15,690 sh (-81.43%)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:FPRX, OTCPK:BVNRY, NAS:INVA, NYSE:EBS, OTCPK:MPSYY, NAS:ACOR, NAS:ALDR, NAS:HALO, OTCPK:PFSCF, NAS:LXRX, NAS:RGEN, NAS:CORT, NAS:XLRN, NAS:SRPT, OTCPK:BPMUF, NAS:AMRN, NAS:INSM, NAS:ARRY, NAS:INSY, NYSE:CBM » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Top Ranked Articles about Puma Biotechnology Inc

Sam Isaly Purchases Stake in Puma Biotechnology Company is close to 3-year low in price with no debt
Guru Samuel Isaly purchased a 142,000-share stake in Puma Biotechnology Inc. (NASDAQ:PBYI) in the first quarter. Read more...

Ratios

vs
industry
vs
history
PB Ratio 12.91
PBYI's PB Ratio is ranked lower than
99.99% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. PBYI: 12.91 )
Ranked among companies with meaningful PB Ratio only.
PBYI' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.91
Current: 12.91
0
12.91
EV-to-EBIT 0.56
PBYI's EV-to-EBIT is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. PBYI: 0.56 )
Ranked among companies with meaningful EV-to-EBIT only.
PBYI' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.56
Current: 0.56
0
0.56
EV-to-EBITDA 0.56
PBYI's EV-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. PBYI: 0.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
PBYI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.56
Current: 0.56
0
0.56
Current Ratio 3.12
PBYI's Current Ratio is ranked lower than
99.99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PBYI: 3.12 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.45 Max: 91.42
Current: 3.12
0.67
91.42
Quick Ratio 3.12
PBYI's Quick Ratio is ranked lower than
99.99% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. PBYI: 3.12 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 5.45 Max: 91.42
Current: 3.12
0.67
91.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.20
PBYI's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. PBYI: -4.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PBYI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -112.2  Med: -58 Max: -4.2
Current: -4.2
-112.2
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.83
PBYI's Price-to-Net-Cash is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. PBYI: 17.83 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PBYI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.69  Med: 14.73 Max: 60.47
Current: 17.83
4.69
60.47
Price-to-Net-Current-Asset-Value 15.81
PBYI's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. PBYI: 15.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PBYI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.26  Med: 13.94 Max: 55.83
Current: 15.81
4.26
55.83
Price-to-Tangible-Book 12.91
PBYI's Price-to-Tangible-Book is ranked lower than
99.99% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PBYI: 12.91 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PBYI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.17  Med: 13.03 Max: 50.75
Current: 12.91
4.17
50.75
Earnings Yield (Greenblatt) % 178.60
PBYI's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. PBYI: 178.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PBYI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 178.6
Current: 178.6
0
178.6

More Statistics

EPS (TTM) $ -8.16
Beta0.17
Short Percentage of Float34.58%
52-Week Range $19.74 - 73.27
Shares Outstanding (Mil)36.82

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 52 411 607
EPS ($) -7.87 -7.07 -0.44 2.81
EPS without NRI ($) -7.87 -7.07 -0.44 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:PBYI

Headlines

Articles On GuruFocus.com
Sam Isaly Purchases Stake in Puma Biotechnology May 03 2016 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference Feb 14 2017
Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Feb 08 2017
Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results? Feb 03 2017
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272 Jan 09 2017
Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI Jan 09 2017
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events Jan 06 2017
Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer... Jan 06 2017
Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer... Jan 06 2017
PUMA BIOTECHNOLOGY, INC. Financials Jan 05 2017
Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Jan 03 2017
Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Dec 19 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Dec 19 2016
Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Dec 19 2016
Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect Dec 08 2016
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events Dec 08 2016
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant... Dec 08 2016
Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant... Dec 07 2016
Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2... Dec 07 2016
Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards Dec 07 2016
CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib)... Dec 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)